Prevention of diabetic nephropathy: From microalbuminuria to end-stage renal insufficiency;Prévention de la néphropathie diabétique: De la microalbuminurie à l'insuffisance rénale terminale

Revue Medicale de Liege

Volumn 58, Issue 5, 2003, Pages 297-306

  Weekers, L ^a,b   Scheen, A J ^a   Rorive, G ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Policliniques L Brull   (Belgium)

Author keywords

Chronic renal failure; Diabetic nephropathy; Drug treatment; Review

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CALCIUM ANTAGONIST; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; FUROSEMIDE; GLYCOSAMINOGLYCAN; INSULIN; IRBESARTAN; LISINOPRIL; NITROFURANTOIN; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; TRIMETHOPRIM; UNINDEXED DRUG; VALSARTAN; VERAPAMIL; VITAMIN D;

CLINICAL FEATURE; CLINICAL TRIAL; DIABETES CONTROL; DIABETIC NEPHROPATHY; DIETARY INTAKE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; EXTRACELLULAR MATRIX; GLOMERULUS FILTRATION; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; PROGNOSIS; PROTEIN RESTRICTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; ULTRAFILTRATION;

DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 0038303471     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Weekers L, Scheen AJ, Lefebvre PJ. - Comment j'explore ... la néphropathie diabétique. Première partie: micro- et macro-albuminurie. Rev Med Liege, 1998, 53, 494-498.
2. Kimmelstiel P. - Basement membrane in diabetic glomerulosclerosis. Diabetes, 1966, 15, 61-63.
3. Mogensen CE, Christensen CK, Vittinghus E. - The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes, 1983, 32 Suppl 2, 64-78.
4. The Diabetes Control and Complications (DCCT) Research Group. - Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int, 1995, 47, 1703-1720.
5. American Diabetes Association. - Standards of medical care for patients with diabetes mellitus. Diabetes Care, 2003, 26 Suppl 1, S33-S50.
6. The Microalbuminuria Captopril Study Group. - Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia, 1996, 39, 587-593.
7. The EUCLID Study Group. - Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet, 1997, 349, 1787-1792.
8. Gambaro G, Kinalska I, Oksa A, et al. - Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol, 2002, 13, 1615-1625.
9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352, 837-853.
10. Hypertension in Diabetes Study (HDS). - I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens, 1993, 11, 309-317.
11. UK Prospective Diabetes Study Group. - Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ, 1998, 317, 713-720.
12. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med, 1997, 157, 2413-2446.
13. Estacio RO, Jeffers BW, Gifford N, et al. - Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care, 2000, 23 Suppl 2, B54-B64.
14. Hansson L, Zanchetti A, Carruthers SG, et al. - Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet, 1998, 351, 1755-1762.
15. Tatti P, Pahor M, Byington RP, et al. - Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care, 1998, 21, 597-603.
16. Estacio RO, Jeffers BW, Hiatt WR, et al. - The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med, 1998, 338, 645-652
17. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). - Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA, 2002, 288, 2981-2997.
18. Adler AI, Stevens RJ, Manley SE, et al. - Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int, 2003, 63, 225-232.
19. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med, 2001, 345, 870-878.
20. Viberti G, Wheeldon NM. - Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation, 2002, 106, 672-678.
21. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet, 2000, 355, 253-259.
22. Philips JC, Weekers L, Scheen AJ. - L'étude CALM ou intérêt de combiner un inhibiteur de l'enzyme de conversion et un antagoniste du récepteur de type 1 de l'angiotensine II dans le traitement de la néphropathie diabétique. Rev Med Liège, 2001, 56, 126-128.
23. Mogensen CE, Neldam S, Tikkanen I, et al. - Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ, 2000, 321, 1440-1444.
24. Gaede P, Vedel P, Larsen N, et al. - Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 2003, 348, 383-393.
25. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis, 2002, 39 (Suppl 2), S1-246.
26. Delanaye P, Chapelle JP, Ferir AM, et al. - La mesure du débit de filtration glomérulaire en clinique quotidienne. Rev Med Liege, 2003, 58, 95-100.
27. Fioretto P, Steffes MW, Sutherland DE, et al. - Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med, 1998, 339, 69-75.
28. Lewis EJ, Hunsicker LG, Bain RP, et al. - The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med, 1993, 329, 1456-1462.
29. American Diabetes Association. - Diabetic nephropathy. Diabetes Care, 2003, 26 (Suppl 1), S94-s98.
30. Klahr S, Levey AS, Beck GJ, et al. - The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med, 1994, 330, 877-884.
31. Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. - Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int, 2002, 62, 220-228.
32. Weekers L, Krzesinski JM. - Etude clinique du mois. Rôle néphroprotecteur des antagonistes du récepteur de l'angiotensine II (ARA) dans le diabète de type 2: résultats des études IDNT et RENAAL. Rev Med Liege, 2001, 56, 723-726.
33. Brenner BM, Cooper ME, de Zeeuw D, et al. - Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 2001, 345, 861-869.
34. Lewis EJ, Hunsicker LG, Clarke WR, et al. - Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 2001, 345, 851-860.
35. Waybill MM, Waybill PN. - Contrast media-induced nephrotoxicity: identification of patients at risk and algorithms for prevention. J Vasc Interv Radiol, 2001, 12, 3-9.
36. Tepel M, van der Giet M, Schwarzfeld C, et al. - Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med, 2000, 343, 180-184.
37. Solomon R, Werner C, Mann D, et al. - Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med, 1994, 331, 1416-1420.
38. Harding GK, Zhanel GG, Nicolle LE, et al. - Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med, 2002, 347, 1576-1583.
39. Kuriyama S, Tomonari H, Yoshida H et al. - Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron, 1997, 77, 176-185.
40. Xue JL, St Peter WL, Ebben JP et al. - Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis, 2002, 40, 1153-1161.